Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 75

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 75
---
 in the Graphic 2 below, created in collaboration with Smart Assays Biotechnologies Ltd. The figure depicts the concentration of free iron (Fe²⁺) in the presence of Telomir-1 (T1) and various ions. When Telomir-1 is introduced, the concentration of free iron decreases (indicated by the shift from the blue point to the orange point). This is direct evidence for the binding of iron to T1, reducing its free ion concertation in the solution. However, the addition of copper (Cu²⁺) at varying concentrations leads to an exchange between bound iron and copper, resulting in the release of previously bound iron and restoration of free iron levels in solution. This is evidenced by an increase in free iron concentration, corresponding to the amount of copper added. In contrast, zinc does not induce an exchange effect on the binding of iron to Telomir-1, indicating a lower affinity of Zinc to Telomir-1.

Graphic 2: Telomir-1 is binding to iron. Copper, but not zinc can replace bound iron by Telomir-1

Telomir-1’s therapeutic rationale in cancer lies in its integrated targeting of two cancer hallmarks: dysregulated metal metabolism and epigenetic silencing of tumor-suppressor genes. Its primary targets are iron-dependent histone demethylase enzymes (KDM2A, KDM2B, KDM6B), which are overexpressed in many cancers and drive transcriptional reprogramming. By inhibiting these enzymes, Telomir-1 restores balanced epigenetic control — reactivating silenced tumor suppressors such as MASPIN/SERPINB5, RASSF1A, STAT1, CASP8, and GSTP1 and reducing oncogenic drivers (e.g., CDKN2A).
In laboratory studies using human TNBC cells, Telomir-1 caused a dose-dependent decrease in cell viability, accompanied by shutdown of cellular-energy pathways and mitochondrial function. The effect was reversed by iron supplementation, confirming iron-dependent activity. These findings suggest that Telomir-1 may restore the body’s natural “kill-and-clean” defenses by rebalancing apoptosis, detoxification, and metabolic regulation through coordinated effects on iron homeostasis and epigenetic control.

Our Market Opportunity and Market Advantage

The international market opportunity for Telomir-1 is significant, driven by rising global incidence of breast cancer and the increased demand for therapies addressing age-related diseases. The global breast cancer